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Abstract
BACKGROUND
Direct-acting antiviral agents (DAAs) are extremely effective in eradicating
hepatitis C virus (HCV) in chronically infected patients. However, the protective
role of the sustained virologic response (SVR) achieved by second- and third-
generation DAAs against the onset of hepatocellular carcinoma (HCC) and
mortality is less well established.
AIM
To examine the occurrence of HCC or death from any cause in a retrospective-
prospective study of patients treated with DAAs.
METHODS
Patients were enrolled from a tertiary academic hospital center for liver disease
management that collects subject data mainly from northeastern Italy. The study
was conducted in 380 patients (age: 60 ± 13 years, 224 males, 32% with cirrhosis)
treated with DAAs with or without SVR (95/5%), with a median follow up of 58
wk (interquartile range: 38-117). The baseline anthropometric features, HCV viral
load, severity of liver disease, presence of extra-hepatic complications, coinfection
with HIV and/or HBV, alcohol consumption, previous interferon use, alpha-
fetoprotein levels, and renal function were considered to be confounders.
RESULTS
The incidence rate of HCC in patients with and without SVR was 1.3 and 59 per
100 person-years, respectively (incidence rate ratio: 44, 95%CI: 15-136, P < 0.001).
Considering the combined endpoint of HCC or death from any cause, the hazard
ratio (HR) for the SVR patients was 0.070 (95%CI: 0.025-0.194, P < 0.001). Other
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independent predictors of HCC or death were low HCV viremia (HR: 0.808, P =
0.030), low platelet count (HR: 0.910, P = 0.041), and presence of mixed
cryoglobulinemia (HR: 3.460, P = 0.044). Considering SVR in a multi-state model,
the independent predictors of SVR achievement were absence of cirrhosis (HR:
0.521, P < 0.001) and high platelet count (HR: 1.019, P = 0.026). Mixed
cryoglobulinemia predicted the combined endpoint in patients with and without
SVR (HR: 5.982, P = 0.028 and HR: 5.633, P = 0.047, respectively).
CONCLUSION
DAA treatment is effective in inducing SVR and protecting against HCC or death.
A residual risk of HCC persists in patients with advanced liver disease or with
complications, such as mixed cryoglobulinemia or renal failure.
Key words: Direct-acting antiviral agents; Hepatitis C virus; Mixed cryoglobulinemia;
Sustained virologic response; Cirrhosis; Survival analysis
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Core tip: The protective role of a sustained virologic response (SVR) achieved by direct-
acting antiviral agents (DAAs) against the chronic consequences of hepatitis C virus
(HCV) infection is not well established. We examined the occurrence of hepatocellular
carcinoma (HCC) or death from any cause in a retrospective-prospective study at our
tertiary academic hospital center for liver disease management. We confirmed that DAA
treatment is very effective in inducing SVR in HCV-infected patients and in protecting
patients against HCC development or death. However, a residual risk of HCC persists,
particularly in patients with advanced liver disease or with extra-hepatic HCV-related
complications.
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URL: https://www.wjgnet.com/1007-9327/full/v25/i40/6094.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i40.6094
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is highly prevalent in many areas of the
world and, because of its serious associated hepatic and extrahepatic complications, it
constitutes an important burden for the global health system[1]. Chronic HCV infection
can cause both liver disease [cirrhosis and hepatocellular carcinoma (HCC)] and
extrahepatic diseases (lymphomas, vasculitis, progressive renal failure) that could
lead to patient death[2]. The classic treatment of HCV infection with interferon-based
regimens has shown a low efficacy in eradicating HCV infection,  particularly in
patients with a high grade of liver fibrosis, and cannot be offered to patients with
more severe liver disease or several comorbidities due to multiple severe adverse
effects[3,4].
New interferon-free therapies based on combinations of direct-acting antiviral
agents (DAAs) have progressively improved HCV eradication, granting a sustained
virologic response (SVR) in more than 95% of patients with fewer adverse effects than
those  treated  with  interferon  therapy[5].  However,  HCV  eradication  following
treatment  with  DAAs  has  not  provided  clear  evidence  of  a  beneficial  effect  in
reducing HCC development in the short term or death in those without advanced
liver disease[6]. In fact, some studies have suggested an increased prevalence of early
HCC recurrence after  treatment  with DAAs in  patients  with a  previously cured
HCC[7,8].
In Italy, the prevalence of HCV infection is among the highest in Western Europe,
reaching 2% of seropositivity and a chronic viremic rate close to 73%[1]. According to
the European Medicines Agency guidelines[9],  DAAs have been approved by the
Italian Medicines Agency (AIFA) since 2014, and they have been made available for
HCV-infected patients with advanced liver fibrosis or with significant HCV-related
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extrahepatic complications. Since 2017, the treatment has been extended to patients
with less advanced liver disease.
In this study, we characterized chronic HCV-infected patients and, after treatment
with second- and third-generation interferon-free DAA regimens, we followed the
patients  for  a  median of  58  weeks.  The aim of  this  study was to  retrospectively
analyze  the  predictors  of  both  SVR  and  new  occurrence  of  HCC  or  death  after
interferon-free DAA treatment. For this purpose, we have used the classic survival
analysis and a more sophisticated multi-state survival model where SVR achievement
was introduced as a time-dependent variable.
MATERIALS AND METHODS
Patients of any age, sex, and race included in the Registry of Drug Monitoring for
DAA use were considered for inclusion in this retrospective study, and the enrollment
period lasted from January 2015 to January 2019. The patients were enrolled from a
tertiary academic hospital center for liver disease management that collects subject
data mainly from northeastern Italy. Patients were included if they had documented
HCV chronic viremia and criteria for using DAAs according to the recommendations
of the AIFA (Table S1 of the supplemental material) and the European Association for
the Study of the Liver (EASL)[10,11]. Patients were excluded from the analysis if, after
inclusion, they did not start DAA therapy or did not complete DAA treatment for
reasons other than adverse effects. Patients were also excluded if they had incomplete
data  or  were  lost  to  follow  up.  The  names  of  the  DAAs  used  are  specified  in
Table S2 of the supplemental material.
Some patients in the study had been previously treated with interferon-based
regimens  without  achieving  SVR  or  with  adverse  effects  that  precluded  the
continuation of therapy. These patients were subsequently treated with interferon-
free DAAs and were included in the study. The choice of DAAs was made according
to  the  EASL guidelines  and under  the  surveillance  of  two expert  hepatologists.
Second- and third-generation DAAs were used with or without ribavirin according to
the HCV genotype and inclusion criteria. Treatment was continued for 12 wk, and
SVR was defined as undetectable HCV RNA at 12 and 24 wk after the end of therapy.
Those patients who did not achieve SVR after 12 wk or did not maintain SVR after 24
wk were considered “nonresponders” or “relapsers”, respectively, and were treated
again with different genotype-specific DAAs for another 12 wk (rescue treatment). If
the first or rescue treatment with DAAs achieved SVR at 12 and 24 wk, the patients
were considered “responders”; otherwise, the patients remained “nonresponders”.
Liver  fibrosis  was  assessed  by  either  liver  biopsy  or  transient  elastography
(FibroScan TM®,  EchoSensTM,  Paris,  France),  and the results  were converted to  a
Metavir score[12]. Cirrhosis was determined by the presence of suggestive clinical signs
(altered serum aminotransferases levels,  platelet  counts,  coagulation parameters,
gamma-glutamyl-aminotransferase levels, total bilirubin levels, and serum albumin
levels) and/or the presence of signs of portal hypertension (ultrasound splenomegaly
and  endoscopic  esophageal  or  gastric  varices),  and  a  Metavir  score  of  F4  (or
corresponding Ishak)[13], or a liver stiffness measured by transient elastography higher
than 14.5 kPa. Patients with cirrhosis were ranked by the Child-Turcotte-Pugh and
MELD scores[14].
All patients were evaluated before starting DAAs and every 3 mo for 1 year by
clinical, biochemical, and ultrasound examinations. Thereafter, the follow up was
established according to hepatic disease severity. Regular medical controls varied
from  every  1  to  6  mo  per  patient.  At  baseline,  we  collected  general  clinical
characteristics,  anthropometric  variables,  and  hemochromocytometric  and
coagulation parameters and assessed liver and kidney functions, plasma glucose and
alpha-fetoprotein levels and the presence of cryoglobulins. The body mass index was
calculated  as  the  body  weight  divided  by  the  squared  height  in  meters.  The
glomerular filtration rate was estimated by the Modification of Diet in Renal Disease
study equation with 4 variables. The presence of diabetes was documented according
to the intake of oral antidiabetic agents and/or the administration of insulin therapy
or by fasting blood glucose higher than 125 mg/dL on two separate days. Alcohol
consumption was considered when the intake was equal to or greater than 20 g/d of
ethanol for both sexes.
The presence of HCC was suspected by ultrasound examination and/or elevated
alpha-fetoprotein levels (> 400 ng/mL) and was confirmed by contrast-enhanced
computed tomography (CT) or magnetic resonance imaging (MRI). When doubts
persisted, CT-guided liver biopsy was performed. Patients with HCC were staged
according to the Barcelona Clinic Liver Cancer system and were treated, whenever
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appropriate, by surgical resection according to the Milan criteria[15,16]. Unresectable
HCC was treated by liver transplantation, percutaneous lesion radiofrequency or
ethanol ablation, or trans-arterial chemoembolization. Patients with HCV viremia and
previous HCC that had been treated by surgical resection, liver transplantation, or
radical local ablation were considered cured after radiological confirmation (complete
radiological response). These patients were treated with DAAs after confirmation of
the complete  radiological  response according to  the Italian guidelines  and were
included in the study. During the follow up, the occurrence of de-novo (new) HCC or
death from any cause was registered for all patients until the end of the study. The
patient  data  and  informed  consent  were  collected  according  to  Italian  laws  on
observational retrospective studies and the Italian Data Protection Authority. The
study was approved by the Institutional Review Board of the University of Udine.
Laboratory and radiological methods
HCV infection was suspected by the detection of serologic anti-HCV antibodies using
a standard immunoassay and was confirmed by the measurement of viremia using
quantitative RNA analysis (Abbott RealTime HCV, Abbott, Rungis, France). HIV and
HBV coinfections were evaluated by standard methods in all HCV-positive patients.
The  genotype  of  HCV  was  established  by  NS5b  gene  sequencing[17].  Blood  and
coagulation variables, plasma aminotransferases, gamma-glutamyl-aminotransferase,
alkaline phosphatase, total bilirubin, creatinine, and glucose levels were assessed by
automated  laboratory  methods.  The  prothrombin  time  was  normalized  using
standard plasma and was expressed as the international  normalized ratio (INR).
Plasma albumin was measured using a colorimetric method (ALB2; Roche cobas®)
and an automated system (Roche/Hitachi Cobas c 701, Roche Diagnostics GmbH,
Mannheim). Cryoglobulins were assessed at baseline according to Vermeersch et al[18].
Specifically,  the  blood  was  clotted  for  1  h,  and  the  serum  was  separated  by
centrifugation at 37 °C and refrigerated at 4 °C to allow cryoglobulin precipitation
(cryocrit)  over  7  d.  The  cryoglobulin  protein  concentration  was  measured  by
spectrophotometry, and the proteins were characterized after rewarming at 37 °C
using an immunologic assay. Only type II or III mixed cryoglobulinemia (MC) was
considered potentially linked to HCV infection[2]. We considered a cryocrit greater
than 1% to be clinically significant. The plasma alpha-fetoprotein level was measured
using an immunoenzymatic chemiluminescence method.
Contrast-enhanced CT and MRI examinations to assess upper abdomen organs
were performed by standardized methods using a 64-row multidetector CT scanner
(Discovery HD 750, GE Healthcare, Milwaukee, WI, United States) and a 3.0-T magnet
using  a  32-channel  surface  coil  (Achieva,  Philips  Medical  System,  Best,  the
Netherlands),  respectively.  Liver  biopsies  were  evaluated  by  an  expert  liver
histopathologist.
Statistical methods
The data are presented as the means ± standard deviation or medians [interquartile
range (IQR)] when appropriate. The normal distribution of variables was assessed by
histogram analysis and the Shapiro-Wilks test for normality. Skewed variables were
log transformed to achieve a normal distribution. Proportions were presented as
counts  (%).  The  mean  difference  was  assessed  by  student’s  t-test  or  by  the
nonparametric Wilcoxon-Mann-Whitney test when appropriate. Proportions were
analyzed as contingency tables, and differences were assessed by Fisher’s exact test.
Correlation  analysis  was  performed  by  calculating  the  Pearson’s  correlation
coefficient. The variance in the continuous variables across factor levels was assessed
by one-way analysis of variance (ANOVA), and Tukey’s method was used to correct
for multiple comparisons. The incidence rate and incident rate ratio with 95%CIs were
calculated as measures of incidence and for comparative purposes (analyzed by a chi-
Squared test). Kaplan-Meier curves with a 95%CI and frequency tables were used to
represent the event rates over time, and the nonparametric log-rank test was used to
assess significant differences. Factors associated with the event rate were analyzed by
Cox’s proportional hazards analysis in univariate and multivariate models, and the
results were expressed as hazard ratios (HRs) at 95%CIs. To analyze the predictors of
SVR achievement and the predictors of HCC or death occurrence with or without SVR
achievement,  multi-state analysis with 3 states (Figure 1)  was conducted.  In this
model, SVR was considered as a time-dependent variable, and Cox’s proportional
hazards were measured for  each of  the 3 state  transitions using a clock-forward
approach in a Markov chain model (Cox-Markov model)[19].  The multi-state Cox-
Markov model is an extension of the classical survival analysis; with this model, we
investigated the effect of different baseline cofactors for each disease state[20].
Multivariate model selection was assessed by the evaluation of the best model
starting from a model that included age and sex and considered all other variables
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Figure 1
Figure 1  Multi-state transition model. DAAs: Direct-acting antiviral agents; SVR: Sustained virologic response;
HCC: Hepatocellular carcinoma.
with univariate statistical or biological relevance by a stepwise forward approach
based on the Akaike information criterion[21]. For statistical analysis, we used software
R (The R Foundation for Statistical Computing, Vienna, Austria, version 3.5.2) using
the “epiR” (version 0.9-99), “survival” (version 2.43-3), “mstate” (version 0.2.11), and
“MASS” (version 7.3-51.1) packages[22].
RESULTS
The study cohort comprised 399 patients who were prescribed interferon-free DAAs.
Two of the patients did not initiate DAAs because of alcohol abuse or decompensated
cirrhosis, two patients did not complete DAA treatment because they did not comply
with the therapy, and 15 patients were lost to follow up or had incomplete data. The
remaining 380 patients were included in the analysis. Cirrhosis was diagnosed in 122
patients before starting DAA treatment. Eight patients had a previous diagnosis of
HCC that  was  cured  by  orthotopic  liver  transplantation  in  six  patients,  and  by
surgical resection or percutaneous radiofrequency in the remaining two patients. We
observed no significant interactions between DAAs and immunosuppressive agents
that  led  us  to  modify  the  dose  or  drug  type.  The  frequencies  of  the  different
interferon-free  DAAs  used  and  the  genotypes  of  HCV  are  reported  in
Supplemental Tables S2 and S3, respectively. DAA treatment was effective in 362
patients (95%), and the overall incidence rate of HCC was 3.2 per 100 person-years.
The incidence rate  of  HCC in patients  who did not  achieve SVR was 59 per  100
person-years, whereas it was 1.3 per 100 person-years in those with SVR (incidence
rate ratio: 44, 95%CI: 15-136, P < 0.001). Five patients interrupted DAA treatment for
adverse events, 1 in the group with SVR and 4 in the group without SVR (P < 0.001).
The frequency of different adverse events reported during treatment is presented in
Supplemental Table S4.
At baseline, the patients with SVR had a higher HCV viral load, platelet count, and
plasma albumin levels than the patients without SVR, and the patients with SVR a
lower occurrence of previous HCC, prevalence of cirrhosis, relapse of HCV infection
after  initial  DAA treatment,  and lower  Metavir  scores,  INR,  and plasma alpha-
fetoprotein levels (Table 1) than the patients without SVR. Patients who developed
HCC during the follow up after DAA therapy had, at baseline, a higher occurrence of
previous HCC, relapse of HCV infection after initial DAA treatment, presence of
plasma cryoglobulins, higher Metavir score, and prevalence of cirrhosis, INR, and
plasma alpha-fetoprotein levels;  these patients also had a lower HCV viral  load,
plasma albumin levels, and platelet count than patients without HCC (Table 1).
The baseline age, sex, BMI, alcohol intake, presence of diabetes, renal function, use
of ribavirin in association with DAAs, previous use of interferon and plasma total
bilirubin levels were not associated with the achievement of SVR or the development
of HCC (Table 1).  Although a different proportion between the type of inclusion
criteria and presence of HCC was observed, no differences were seen between the
inclusion criteria and SVR and between the HCV genotype and presence of SVR or
HCC (Supplemental Table S3), whereas a difference in the proportion between the
DAAs used and the presence of SVR or HCC was observed (P = 0.010 and P < 0.001,
respectively;  Supplemental  Table  S2).  DAA treatment  induced SVR similarly  in
patients who had previously used interferon and in those who had not, at rates of
94.8% and 95.5%, respectively. HCC developed in 5.8% or 3.7% of patients who had
used interferon or not previously, respectively. The differences between these groups
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Table 1  Characteristics of the patients treated for hepatitis C virus infection with direct-acting antiviral agents according to the sustained
virologic response and hepatocellular carcinoma development during follow up
Variable All patients (n = 380) No SVR (n = 18) SVR (n = 362) P value No HCC (n = 363) HCC (n = 17) P value
General clinical characteristics
Age (yr) 60 ± 13 62 ± 10 59 ± 13 NS 59 ± 13 61 ± 9 NS
Male, n (%) 224 (58.9) 14 (77.8) 210 (58.0) NS 213 (58.7) 11 (64.7) NS
BMI (kg/m2) 24.9 ± 3.7 24.6 ± 2.7 24.9 ± 3.7 NS 24.9 ± 3.7 24.2 ± 3.2 NS
Alcohol use, n (%) 17 (4.5) 2 (11.1) 15 (4.1) NS 16 (4.4) 1 (5.9) NS
Diabetes, n (%) 48 (12.6) 4 (22.2) 44 (12.1) NS 44 (12.1) 4 (23.5) NS
Plasma creatinine (mg/dL) 0.86 ± 0.24 1.03 ± 0.42 0.86 ± 0.23 NS 0.86 ± 0.24 0.97 ± 0.30 NS
eGFR (mL/min/1.73 m2) 87 ± 25 91 ± 18 87 ± 25 NS 87 ± 25 86 ± 16 NS
HCV infection-related variables
HCV viremia (n × 103) 956 (203-2944) 297 (47-1442) 977 (219-3059) 0.033 967 (219-3049) 244 (36-1864) NS
HIV coinfection, n (%) 8 (2.1) 0 8 (100) - 8 (100) 0 -
Previous use of interferon, n (%) 137 (36.0) 7 (38.9) 130 (35.9) NS 129 (35.5) 8 (47.1) NS
Use of ribavirin association, n
(%)
89 (23.4) 5 (27.8) 84 (23.2) NS 84 (23.1) 5 (29.4) NS
SVR, n (%) 362 (95.3) - 362 (100) - 355 (97.8) 10 (58.8) < 0.001
Time to SVR (wk) 12 (12-13) - 12 (12-13) - 12 (12-12) 15 (13-23) < 0.001
HCV relapse, n (%) 20 (5.3) 12 (66.7) 8 (2.2) < 0.001 13 (3.6) 7 (41.2) < 0.001
Mixed cryoglobulinemia, n (%) 35 (9.2) 4 (22.2) 31 (8.6) NS 30 (8.3) 5 (29.4) 0.014
Liver structure and function variables
Metavir score 2.6 ± 1.2 3.7 ± 0.6 2.6 ± 1.2 < 0.001 2.6 ± 1.2 3.9 ± 0.3 < 0.001
Cirrhosis, n (%) 122 (32.1) 14 (77.8) 108 (29.8) < 0.001 107 (29.5) 15 (88.2) < 0.001
Plasma albumin (g/L) 41.0 ± 5.4 37.6 ± 6.3 41.2 ± 5.3 0.027 41.4 ± 5.4 38.7 ± 5.0 0.047
Plasma total bilirubin (g/dL) 0.79 ± 0.41 0.92 ± 0.50 0.78 ± 0.41 NS 0.78 ± 0.41 0.94 ± 0.47 NS
Plasma alpha-fetoprotein
(ng/mL)
4.10 (2.87-7.10) 6.30 (5.20-8.70) 4.10 (2.75-7.05) 0.012 4.10 (2.70-6.80) 8.00 (4.95-10.80) 0.001
Platelet count (n × 103/mL) 167 ± 67 114 ± 67 170 ± 66 0.003 170 ± 66 98 ± 62 < 0.001
INR 1.05 ± 0.12 1.14 ± 0.19 1.04 ± 0.11 0.038 1.05 ± 0.11 1.17 ± 0.17 0.013
HCC-related variables
Previous HCC, n (%) 8 (2.1) 3 (16.7) 5 (1.4) 0.004 5 (1.4) 3 (17.6) 0.004
HCC, n (%) 17 (4.5) 10 (55.5) 7 (1.9) < 0.001 - 17 (100) -
Time to HCC (wk) 26 (17-65) 25 (12-57) 40 (25-63) NS - 26 (17-65) -
Death, n (%) 8 (2.1) 3 (16.7) 5 (1.4) 0.004 4 (1.1) 4 (23.5) < 0.001
Time to death (wk) 65.5 (50.5-126.8) 40 (28-79) 76 (55-150) NS 65 (55-95) 79 (34-127) NS
HCV: Hepatitis C virus; SVR: Sustained virologic response; HCC: Hepatocellular carcinoma; BMI: Body mass index; eGFR: Estimated glomerular filtration
rate; NS: Not significant; INR: International standardized ratio; HIV: Human immunodeficiency virus.
were not significant. Three of eight patients with a previously cured HCC showed
recurrence  of  HCC,  and  all  3  of  these  patients  did  not  achieve  SVR  after  DAA
treatment. The remaining 5 patients achieved SVR and did not develop HCC. The log
of the HCV viral load was directly associated with the log of the platelet count (P =
0.014), and a significant difference was found between the log HCV viral load across
Metavir scores (P  = 0.014); specifically, the viral load in the Metavir F4 score was
significantly lower than that in the F3 score (P = 0.032 after Tukey’s correction). An
inverse relationship was found between the platelet count across Metavir scores (P <
0.001).
Patients with MC were more frequently of the female sex (95% vs 83%, P < 0.001),
older (64 ± 10 vs 59 ± 13 years, P = 0.005), and with a worse renal function (eGFR 79 ±
24 vs 88 ± 25 mL/min/1.73 m2, P = 0.039) than patients without MC at baseline. No
association was found between MC and the Metavir  score,  presence of  cirrhosis,
platelet count, albumin levels or INR. HIV coinfection was not associated with SVR or
HCC. No HBV coinfection was detected in all included patients.
The effect of SVR on the combined endpoint of a new HCC occurrence or death
from any cause during the follow up is represented by Kaplan-Meier curves in Figure
2. In a median follow up of 58 wk (IQR 38-117), the patients with SVR had a higher
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survival  rate  free  from HCC than patients  who did not  achieve SVR (HR:  0.035,
95%CI: 0.015-0.084, P < 0.0001, Figure 2). In classical Cox’s multivariate proportional
hazards analysis, the factors that best and independently predicted the combined
endpoint were the log of HCV viremia (HR: 0.808, 95%CI: 0.666-0.980, P  = 0.030),
platelet count (HR: 0.910, 95%CI: 0.831-0.996, P = 0.041), presence of MC (HR: 3.460,
95%CI: 1.035-11.56, P = 0.044), and presence of SVR (HR: 0.070, 95%CI: 0.025-0.194, P <
0.001). The predictors were independent of age, sex, renal function, and presence of
cirrhosis (Table 2). In Figure 3, we reported the independent effect of both the SVR
and MC status on the combined endpoint of HCC or death from any cause. The effect
of  the  presence  of  cirrhosis  on  the  combined  end-point  by  SVR  achievement  is
represented in Figure S1 of the supplemental material.
Since the baseline hazards did not satisfy the proportional hazards assumption in
the multi-state Cox-Markov model, we used stratified hazards instead of proportional
hazards to assess baseline hazards for each separate state transition, as shown in
Figure 1 (Table 3). The analysis showed that the best and independent predictors of
SVR achievement (transition 1→2) were the absence of cirrhosis (HR: 0.521, 95%CI:
0.404-0.672, P < 0.001) and higher platelet count (HR: 1.019, 95%CI: 1.002-1.036, P =
0.026); the predictor of HCC or death in patients who did not achieve SVR (transition
1→3) was the presence of MC (HR: 5.633, 95%CI: 1.022-31.05, P  = 0.047);  and the
predictors of HCC or death of patients who achieved SVR (transition 2→3) were the
presence of MC (HR: 5.982, 95%CI: 1.217-29.41, P = 0.028), lower platelet count (HR:
0.958, 95%CI: 0.939-0.979, P < 0.001), and lower eGFR (HR: 0.948, 95%CI: 0.915-0.985, P
= 0.005).
DISCUSSION
In this study, HCV-infected patients who achieved SVR after DAA treatment had a
significantly higher survival rate free from new HCC occurrence and a lower rate of
death from any cause than patients who did not achieve SVR. This association was
strongly independent of confounders in a classical survival model where the presence
of  SVR was considered a baseline variable together with age,  sex,  HCV viremia,
presence of cirrhosis, MC, platelet count, and renal function.
Although SVR achievement using interferon-based regimens is a predictor of HCC-
free survival[23], similar evidence is less clear for DAAs. Different retrospective studies
have reported that treatment with these agents did not reduce the incidence of HCC[7]
but can even increase the risk of early HCC recurrence after treatment[7,8]. Conversely,
other studies with larger samples have suggested a strong beneficial effect of SVR on
both the occurrence and recurrence of HCC[24-27]. Our study demonstrated that the
achievement of SVR is robustly associated with a better HCC-free survival than a lack
of SVR and is independent of previous interferon-based regimen use. However, the
lack of a control group precluded the possibility of testing whether DAA treatment
per se can be a risk factor for HCC development, although the overall observed HCC
incidence rate was similar to that in previous studies with different HCV treatments[6].
Notably, it should be considered that patients with fibrosis > F2 (Metavir) or cirrhosis
that  achieved  SVR after  DAA treatment  should  still  need  surveillance  for  their
residual risk to develop HCC[28].
SVR is a condition more frequently achieved in HCV-infected patients with a lower
grade of  liver fibrosis  and less advanced hepatic  disease.  Patients with cirrhosis
and/or a  decompensated liver  disease  are  less  prone to  achieve SVR,  and these
patients are also those with the highest probability of developing HCC and dying due
to several causes[29]. Additionally, in our study, the predictors of SVR achievement
were  a  low Metavir  score  or  the  absence  of  cirrhosis  and  a  high  platelet  count,
indicating the expression of less advanced liver disease. In addition, in patients who
achieved SVR, the signs of portal hypertension and impaired renal function, such as
the  markers  of  advanced  liver  disease,  are  independent  predictors  of  HCC
development and death from any cause. This is an important point, since the use of
DAAs was only recently approved in Italy for HCV patients with less advanced
hepatic disease. In those low-risk patients, the efficacy of HCV eradication on the
prevention of HCC was indeed more pronounced. This extension of DAAs use is
expected to significantly reduce the HCV epidemic and the global burden of HCV-
related complications.
In our study, a low baseline viral load was a predictor of HCC development or
death from any cause. This point has been explored by Duvoux et al[30] who evaluated
the HCV viral load in 3 groups of patients with chronic HCV infection: (1) Without
cirrhosis; (2) With compensated cirrhosis; and (3) With end-stage cirrhotic disease
waiting for liver transplantation[30]. The HCV viral load was significantly lower in
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Table 2  Cox’s proportional hazards analysis for the combined endpoint of hepatocellular
carcinoma occurrence or death from any cause
Univariate analysis Multivariate analysis
Variable HR (95%CI) P value HR (95%CI) P value
Age (yr) 1.003 (0.968-1.040) 0.862 1.008 (0.958-1.060) 0.760
Male (no/yes) 1.334 (0.538-3.308) 0.534 2.492 (0.683-9.089) 0.167
HCV viremia (log n) 0.811 (0.698-0.944) 0.007 0.808 (0.666-0.980) 0.030
Cirrhosis (no/yes) 9.259 (2.705-31.70) < 0.001 3.392 (0.861-13.37) 0.081
Platelet count (n × 104/mL) 0.806 (0.735-0.885) < 0.001 0.910 (0.831-0.996) 0.041
eGFR (10 mL/min/1.73 m2) 0.935 (0.780-1.122) 0.473 0.774 (0.596-1.005) 0.055
Mixed cryoglobulinemia (no/yes) 4.522 (1.822-11.23) 0.001 3.460 (1.035-11.56) 0.044
SVR (no/yes) 0.035 (0.015-0.084) < 0.001 0.070 (0.025-0.194) < 0.001
HCV: Hepatocellular C virus; SVR: Sustained virologic response; HR: Hazard ratio; CI: Confidence interval;
eGFR: Estimated glomerular filtration rate.
end-stage cirrhosis disease than in the other groups and, more interestingly, the viral
load increased after liver transplantation. This inverse relationship occurred despite
the HCV genotype. The authors concluded that HCV replication is lower in end-stage
cirrhotic disease because of a reduced hepatocyte mass and/or an impaired cell-to-cell
virus transmission probably due to extensive liver fibrosis[30].  These HCV chronic
patients were also those with the lowest probability of achieving SVR and highest risk
of developing HCC or dying from any cause. In our study, the inverse association
between the HCV viral load and severity of liver disease has been suggested by the
indirect  relationship  between  the  viral  load  and  Metavir  score,  and  the  direct
relationship between the viral load and platelet count. However, the role of HCV
viremia as a predictive factor of HCC development or mortality in cirrhotic patients
remains controversial[31].
Interestingly, we also observed that the baseline presence of an MC predicted the
probability  of  developing  HCC or  dying  from any cause  independently  of  SVR
achievement.  Asymptomatic  or  symptomatic  MC  is  associated  with  HCV  viral
infection by mechanisms that are not well understood. Generally, stimulation of the B-
lymphocyte system by HCV facilitates the development of immortalized B-cell clones
releasing  IgM  with  rheumatoid  factor  activity  and  the  formation  of
immunocomplexes between immunoglobulins and HCV molecular components that
precipitate in plasma below 37 °C. These immunocomplexes activate complement,
inducing  vascular  inflammation  that  leads  to  vascular  inflammation  and
cryoglobulinemic syndrome[32]. It is not clear how the presence of cryoglobulinemia
could influence SVR achievement and/or HCC development. The study of Passerini
et  al[33]  showed no difference in SVR achievement at  12 wk after  DAA treatment
between HCV patients with and without serum cryoglobulins; however, a previous
meta-analysis of 19 observational studies, with more than 2000 patients enrolled,
demonstrated that the development of cirrhosis was 5 times as frequent in patients
with MC as in those without (OR: 4.90, 95%CI: 3.32-7.15)[34]. Paradoxically, the long-
term  prospective  study  of  Lauletta  et  al [35]  showed  that  the  presence  of  a
cryoglobulinemic  syndrome  is  an  independent  protective  factor  against  the
development of both cirrhosis and HCC, although no difference was found in the
overall  survival  between  patients  with  or  without  cryoglobulins  in  15  years  of
observation[35]. Nevertheless, the prevalence of MC in our study was lower than that
expected from previous studies (40%-60%)[33], likely because of our elevated cut-off
point for MC diagnosis that could have led us to underestimate low-grade MC[18].
This study has several limitations that need to be highlighted. First, we included all
patients who had been treated with DAAs at a single center, without selection criteria
to increase the sample size and improve the statistical power of the study. However,
the study population was heterogeneous, and several unknown confounders could
have influenced the results. Thus, we have used statistical adjustments in inferential
methods  and  performed  multivariate  analyses  with  significant  and  clinically
important confounders, factoring in such heterogeneity as much as possible. Second,
we had a low incidence of events and a low median observational time. This low
incidence is because we included only HCV patients treated with second- and third-
generation DAAs that were introduced in Italy only recently. This point is important
because the low outcome rate together with the elevated SVR achievement rate could
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Figure 2
Figure 2  Kaplan-Meier curves and risk table representing survival free of hepatocellular carcinoma or death from any cause according to sustained
virologic response to hepatitis C virus direct-acting antiviral agents. Plain areas represent the 95% confidence interval. P value by the nonparametric log-rank
test. SVR: Sustained virologic response; HCC: Hepatocellular carcinoma.
have  limited  the  power  of  our  multi-state  Cox-Markov  analysis  to  confirm  a
protective effect of SVR on HCC development and mortality. On the other hand, the
strength of our study is that the use of a multi-state Cox-Markov model has permitted
us to explore more deeply the relationships of the baseline variables with events in
each different disease state, which is not possible with a classical survival Cox model.
Third, the lack of a control group did not permit exploration of the hypothesis of
DAAs as a potential risk factor for HCC development; however, this investigation
was  not  among  the  aims  of  the  study.  Fourth,  the  follow  up  interval  could  be
relatively short  for  HCC development,  at  least  in  a  general  population of  HCV-
infected patients. However, because the national guidelines limits DAA prescription
to patients with advanced or complicated liver disease (Table S1 of supplemental
material), we necessarily treated patients with a high risk of developing HCC in a
shorter period.
In conclusion, we confirmed that DAA treatment is highly effective in eradicating
HCV infection,  and this eradication occurs more frequently in patients with less
advanced liver disease. In addition, HCV-infected patients who achieved SVR after
DAA treatment have a higher survival free from new HCC occurrence or death from
any cause than patients who did not achieve SVR. In a classical survival model, this
association was strongly independent of confounders.
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Table 3  Multi-state Cox-Markov stratified hazards model for transitions in Figure 1
Variable HR 95%CI P value
Transition 1→2
Age (yr) 0.997 0.989-1.005 0.493
Male (no/yes) 0.789 0.615-1.013 0.062
HCV viremia (log n) 0.983 0.940-1.029 0.470
Cirrhosis (no/yes) 0.521 0.404-0.672 < 0.001
Mixed cryoglobulinemia (no/yes) 0.755 0.520-1.098 0.141
Platelet count (n × 104/mL) 1.019 1.002-1.036 0.026
eGFR (10 mL/min/1.73 m2) 1.003 0.998-1.008 0.235
Transition 1→3
Age (yr) 0.975 0.912-1.043 0.466
Male (no/yes) 2.040 0.249-16.74 0.507
HCV viremia (log n) 0.771 0.589-1.009 0.058
Cirrhosis (no/yes) 5.704 0.620-52.51 0.124
Mixed cryoglobulinemia (no/yes) 5.633 1.022-31.05 0.047
Platelet count (n × 104/mL) 0.928 0.981-1.005 0.229
eGFR (10 mL/min/1.73 m2) 1.007 0.970-1.045 0.726
Transition 2→3
Age (yr) 1.019 0.945-1.098 0.625
Male (no/yes) 3.613 0.692-18.88 0.128
HCV viremia (log n) 0.972 0.715-1.321 0.857
Cirrhosis (no/yes) 2.720 0.479-15.44 0.259
Mixed cryoglobulinemia (no/yes) 5.982 1.217-29.41 0.028
Platelet count (n × 104/mL) 0.958 0.935-0.982 < 0.001
eGFR (10 mL/min/1.73 m2) 0.948 0.915-0.985 0.005
HCV: Hepatitis C virus; HR: Hazard ratio; CI: Confidence interval; eGFR: Estimated glomerular filtration rate.
Figure 3
Figure 3  Kaplan-Meier curves and risk table representing survival free of hepatocellular carcinoma or death from any cause according to the presence of
mixed cryoglobulinemia and sustained virologic response to hepatitis C virus direct-acting antiviral agents.P value by nonparametric log-rank test. +: with; -:
without; MC: Mixed cryoglobulinemia; SVR: Sustained virologic response; HCC: Hepatocellular carcinoma.
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ARTICLE HIGHLIGHTS
Research background
Direct-acting antiviral agents (DAAs) are extremely effective in eradicating hepatitis C virus
(HCV) in chronically infected patients. However, the protective role of a sustained virologic
response  (SVR)  achieved  by  second-  and  third-generation  DAAs  against  the  onset  of
hepatocellular carcinoma (HCC) and mortality is less well established.
Research motivation
The main topic of this study was to establish the effectiveness of new generations of DAAs to
induce SVR and to prevent HCC development or mortality in HCV-infected patients. These
patients  were  characterized  by  an  elevated  risk  for  HCC  because  of  their  advanced  or
complicated liver disease. The strength of this study was the use of a multi-state Cox-Markov
model. This model permitted us to explore more deeply the relationships of baseline variables
with events in each different disease state. This last approach is not possible with a classical
survival Cox model.
Research objectives
The  aim  of  this  study  was  to  examine  HCC  occurrence  or  death  from  any  cause  in  a
retrospective-prospective  study  of  patients  treated  with  DAAs  and  to  identify  potential
predictors of SVR achievement and HCC development.
Research methods
The patients were enrolled from a tertiary academic hospital center for liver disease management
that collects subject data mainly from northeastern Italy. The study was conducted using 380
patients (age: 60 ± 13 years, 224 males, 32% with cirrhosis) treated with DAAs with or without
SVR (95/5%), with a median follow up of 58 wk (interquartile range: 38-117).  The baseline
anthropometric features, HCV viral load, severity of liver disease, presence of extra-hepatic
complications, coinfection with HIV and/or HBV, alcohol consumption, previous interferon use,
alpha-fetoprotein levels, and renal function were considered to be confounders. Survival analysis
was conducted using a classical Cox model and a more advanced Cox-Markov multi-state model
that considered SVR as a time-dependent variable that can influence the probability of the
outcome.
Research results
The incidence rates of HCC in patients with and without SVR were 1.3 and 59 per 100 person-
years, respectively (incidence rate ratio: 44, 95%CI: 15-136, P < 0.001). Considering the combined
endpoint of HCC or death from any cause, the hazard ratio (HR) for SVR patients was 0.070
(95%CI: 0.025-0.194, P < 0.001). Other independent predictors of HCC or death were low HCV
viremia (HR: 0.808, P = 0.030), low platelet count (HR: 0.910, P = 0.041), and presence of mixed
cryoglobulinemia (HR: 3.460, P = 0.044). Considering SVR in a multi-state model, independent
predictors of SVR achievement were the absence of cirrhosis (HR: 0.521, P < 0.001) and high
platelet count (HR: 1.019, P = 0.026). Mixed cryoglobulinemia predicted the combined endpoint
in patients with and without SVR (HR: 5.982, P = 0.028 and HR: 5.633, P = 0.047, respectively).
Research conclusions
Treatment with DAAs is very effective in inducing SVR and protecting against HCC or death. A
residual risk for HCC persists in patients with advanced liver disease or disease complicated by
extra-hepatic manifestations, such as mixed cryoglobulinemia and renal failure.
Research perspectives
New generations of DAAs should be recommended to treat all patients with HCV infection
independently of the status of their liver disease or the presence of extra-hepatic manifestations.
Further studies are needed to define a better strategy to treat HCV-infected patients with more
advanced or complicated liver disease.
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